HNB
CCCC icon

Huntington National Bank’s C4 Therapeutics CCCC Stock Holding History

Huntington National Bank’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.92K Buy
+107
New +$366 ﹤0.01% 2259

Other funds holding CCCC

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Huntington National Bank's CCCC Position: Q2 2026 in Review

Huntington National Bank opened a new position in C4 Therapeutics (CCCC) in Q2 2026: 107 shares worth $4.92K. The stake represents ﹤0.01% of the portfolio and ranks #2259 among its holdings.

148 funds tracked by Wall St. Rank hold CCCC as of Q2 2026.

  • Huntington National Bank held 107 shares of C4 Therapeutics worth $4.92K as of Q2 2026.
  • C4 Therapeutics was a new Huntington National Bank position in Q2 2026.
  • C4 Therapeutics made up ﹤0.01% of Huntington National Bank's portfolio in Q2 2026, its #2259 holding.
  • 148 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2026.

Based on Huntington National Bank's 13F filing for Q2 2026, filed 13 Aug 2026.